Rightly so, the Q1 numbers showed revenue increasing over 80% pcp but the 1H numbers are up around 65% pcp. This means the growth in Q2FY22 vs Q2FY21 was was only around 40%. Ballpark numbers but that's what I think disappointment the market.
I am happy giving them the benefit of doubt. Compared to a lot of spec health stocks, PEB looks like they have a beneficial solution. As long as the product is actually going to save the healthcare system money, I'm sure it will eventually get adopted more broadly.
Rightly so, the Q1 numbers showed revenue increasing over 80%...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.25M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1445 | 8.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.9¢ | 15969 | 1 |
View Market Depth
| Last trade - 10.06am 16/06/2025 (20 minute delay) ? |
| PEB (ASX) Chart |
Day chart unavailable